Search for Clinical Trial Results

Sponsored By

Anaplastic Plasmacytoma - 139 Studies Found

Status Study
Completed Study Name: Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-12-05
Interventions:
  • Drug: bortezomib
  • Drug: hydroxychloroquine
Terminated Study Name: Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-12-01
Interventions:
  • Biological: rituximab
  • Drug: lenalidomide
Completed Study Name: Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-11-30
Interventions:
  • Biological: therapeutic autologous lymphocytes
Completed Study Name: High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-09-05
Interventions:
  • Biological: filgrastim
  • Biological: pegfilg
Completed Study Name: Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-08-31
Interventions:
  • Drug: bortezomib IV
Withdrawn Study Name: Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-07-17
Interventions:
  • Drug: Arsenic trioxide Arsenic
Completed Study Name: Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-07-10
Interventions:
  • Biological: CMV pp65 peptide G
Completed Study Name: Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-06-04
Interventions:
  • Biological: bevacizumab
  • Genetic: gene expr
Active, not recruiting Study Name: Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
Condition:
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Pain

Date: 2007-06-04
Interventions:
  • Drug: Pamidronate 90 mg by IV

Completed Study Name: Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Date: 2007-05-23
Interventions:
  • Drug: cyclophosphamide 300 mg/
<<< Previous | Next >>>